The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. (Q27824815)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q59707780)
(P304) 1272-1275
(P407) (Q1860)
(P433) 4
(P478) 319
(P577) Thursday, July 1, 2004
(P921) (Q177094)
(P1433) (Q864228)
(P1476) "The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase" (language: en)
(P2093) Tetsuya Kurosu
Kazuhiko Kakihana
Daisuke Mizuchi
Osamu Miura
other details
description scientific article

External Links